Still seeking an effective "one-two" malaria vaccine punch.
作者信息
Smith Joseph D, Sack Brandon K
机构信息
Seattle Biomedical Research Institute, Seattle, WA 98109, USA.
出版信息
Mol Ther. 2012 Dec;20(12):2198-200. doi: 10.1038/mt.2012.241.
Abstract
摘要
相似文献
1
Still seeking an effective "one-two" malaria vaccine punch.仍在寻找一种有效的疟疾疫苗“组合拳”。
Mol Ther. 2012 Dec;20(12):2198-200. doi: 10.1038/mt.2012.241.
2
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.靶向 MSP1 和 AMA1 的 ChAd63-MVA-vectored 血期疟疾疫苗：在人体中针对蚊子叮咬挑战的功效评估。
Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.
3
Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.一种嵌合恶性疟原虫裂殖子表面蛋白疫苗在夜猴中的免疫原性。
Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5.
4
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.基于攻击前抗体反应预测裂殖子表面蛋白1和顶膜抗原1疫苗对查巴迪疟原虫疟疾的疗效
Clin Vaccine Immunol. 2009 Mar;16(3):293-302. doi: 10.1128/CVI.00230-08. Epub 2008 Dec 30.
5
Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant s25, a Leading Transmission-Blocking Vaccine Candidate.评估一种疟原虫特异性载体蛋白以提高重组s25的产量，重组s25是一种主要的传播阻断疫苗候选物。
Infect Immun. 2017 Dec 19;86(1). doi: 10.1128/IAI.00486-17. Print 2018 Jan.
6
A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.一种编码血液期抗原AMA1和MSP1的间日疟原虫质粒DNA和腺病毒载体疟疾疫苗，在初免/加强异源免疫方案中可部分保护夜猴免受血液期攻击。
Clin Vaccine Immunol. 2017 Apr 5;24(4). doi: 10.1128/CVI.00539-16. Print 2017 Apr.
7
Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.用约氏疟原虫裂殖子表面蛋白1和4/5的组合进行口服免疫可增强对致命性疟疾攻击的保护作用。
Infect Immun. 2004 Oct;72(10):6172-5. doi: 10.1128/IAI.72.10.6172-6175.2004.
8
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.在缺乏γ干扰素或白细胞介素-4的情况下，用顶膜抗原1和裂殖子表面蛋白1免疫诱导对查巴迪疟原虫疟疾的保护作用。
Infect Immun. 2004 Oct;72(10):5605-12. doi: 10.1128/IAI.72.10.5605-5612.2004.
9
A robust neutralization test for Plasmodium falciparum malaria.一种针对恶性疟原虫疟疾的强大中和试验。
J Exp Med. 2001 Jun 18;193(12):F51-4. doi: 10.1084/jem.193.12.f51.
10
The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria.裂殖子表面蛋白1的羧基末端：结构、特异性抗体与疟疾免疫
Parasitology. 2009 Oct;136(12):1445-56. doi: 10.1017/S0031182009990515. Epub 2009 Jul 23.
引用本文的文献
1
Layer-by-Layer Delivery of Multiple Antigens Using Trimethyl Chitosan Nanoparticles as a Malaria Vaccine Candidate.利用三甲基壳聚糖纳米粒作为疟疾疫苗候选物进行多层递药。
Front Immunol. 2022 Aug 17;13:900080. doi: 10.3389/fimmu.2022.900080. eCollection 2022.
本文引用的文献
1
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.靶向 MSP1 和 AMA1 的 ChAd63-MVA-vectored 血期疟疾疫苗：在人体中针对蚊子叮咬挑战的功效评估。
Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.
2
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.疟原虫血期抗原 PfRH5 易受疫苗诱导的交叉株中和抗体的影响。
Nat Commun. 2011 Dec 20;2:601. doi: 10.1038/ncomms1615.
3
Immunology. Another shot at a malaria vaccine.免疫学。疟疾疫苗的又一次尝试。
Science. 2011 Oct 28;334(6055):460-1. doi: 10.1126/science.1213934.
4
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.RTS,S/AS01 疟疾疫苗在非洲儿童中进行的 3 期临床试验的初步结果。
N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.
5
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.腺病毒 5 型载体疟疾疫苗表达 CSP 和 AMA1。B 部分：CSP 成分的安全性、免疫原性和保护效力。
PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868. Epub 2011 Oct 7.
6
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity.经设计可通过肝脏 CD8+T 细胞免疫来提供保护的减毒疟疾疫苗。
Science. 2011 Oct 28;334(6055):475-80. doi: 10.1126/science.1211548. Epub 2011 Sep 8.
7
Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.联合肝期和血期疟疾病毒载体疫苗：研究 CD8+T 细胞干扰的机制。
J Immunol. 2011 Oct 1;187(7):3738-50. doi: 10.4049/jimmunol.1003783. Epub 2011 Aug 29.
8
Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites.经晚期肝脏阶段抑制遗传减毒寄生虫疫苗接种后获得的抗疟免疫力更高。
Cell Host Microbe. 2011 Jun 16;9(6):451-62. doi: 10.1016/j.chom.2011.05.008.
9
Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.评价含有佐剂 AS02A 的恶性疟原虫顶膜蛋白 1、裂殖子表面蛋白 1 或 RTS,S 疫苗单独或同时接种恒河猴的安全性和免疫原性。
Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.
10
Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.表达裂殖子表面蛋白-1的重组病毒疫苗可诱导抗体和T细胞介导的针对疟疾的多阶段保护。
Cell Host Microbe. 2009 Jan 22;5(1):95-105. doi: 10.1016/j.chom.2008.12.004.
Zotero 插件